MiNK Therapeutics
INKT
11 hedge funds and large institutions have $1M invested in MiNK Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
99% more capital invested
Capital invested by funds: $504K → $1M (+$499K)
0.03% more ownership
Funds ownership: 0.11% → 0.14% (+0.03%)
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$161K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$96.7K |
| 3 |
State Street
Boston,
Massachusetts
|
+$21.9K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$20.5K |
| 5 |
BlackRock
New York
|
+$6.64K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$50K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1K |
| 4 |
Morgan Stanley
New York
|
-$827 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AG
1
Artal Group
Luxembourg
| $611K | – | – | – |
|
|
JMPWA
2
JP Morgan Private Wealth Advisors
San Francisco,
California
| $172K | +$161K | +8,150 | New |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $104K | +$96.7K | +4,911 | New |
|
4
Geode Capital Management
Boston,
Massachusetts
| $48K | – | – | – |
|
|
5
State Street
Boston,
Massachusetts
| $23K | +$21.9K | +1,111 | New |
|
|
6
HighTower Advisors
Chicago,
Illinois
| $22K | +$20.5K | +1,040 | New |
|
|
7
BlackRock
New York
| $21K | +$6.64K | +337 | +51% |
|
8
UBS Group
Zurich,
Switzerland
| $1K | – | – | – |
|
9
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$926 | +47 | New |
|
|
BCM
10
Bridgeway Capital Management
Houston,
Texas
| – | -$50K | -3,550 | Closed |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| – | -$2K | -110 | Closed |
|
|
12
Morgan Stanley
New York
| – | -$827 | -42 | -91% |
|
|
13
Fidelity Investments
Boston,
Massachusetts
| – | -$1K | -37 | Closed |
|
14
Wells Fargo
San Francisco,
California
| – | +$20 | +1 | +50% |
|
INKT Hedge Fund Activity: Q3 2022 in Review
11 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q3 2022, worth a combined $1M — up 99% from $504K a quarter earlier.
Fund positioning in INKT was balanced in Q3 2022: 5 funds opened new positions, 5 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was JP Morgan Private Wealth Advisors, opening a new position worth an estimated $161K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $50K sold.
- 11 institutional investors held MiNK Therapeutics (INKT) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $1M of MiNK Therapeutics stock for Q3 2022, up 99% quarter-over-quarter.
- 5 funds opened new MiNK Therapeutics positions in Q3 2022 and 5 closed out, a net change of 0 holders.
- The largest MiNK Therapeutics buyer in Q3 2022 was JP Morgan Private Wealth Advisors, an estimated $161K added.
- The largest MiNK Therapeutics seller in Q3 2022 was Bridgeway Capital Management, an estimated $50K sold.
Based on aggregated 13F filings for Q3 2022.